BioSyent’s Q3 Sales Surge Amid Strategic Moves

Biosyent (TSE:RX) has released an update.

BioSyent Inc. reported its highest-ever quarterly company sales in Q3 2024, with an 8% growth compared to the same quarter last year. The company’s strategic acquisitions and share buybacks have bolstered its financial performance, showing a 13% increase in year-to-date sales, EBITDA, and net income after taxes. These results are supported by the acquisition of Tibelia and the promotion of key pharmaceutical products, positioning BioSyent for continued growth.

For further insights into TSE:RX stock, check out TipRanks’ Stock Analysis page.